You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
紅日藥業(300026.SZ):血必淨注射液列入《新型冠狀病毒肺炎診療方案(試行第六版)》
格隆匯 02-20 11:45

格隆匯2月20日丨紅日藥業(300026.SZ)公佈,2020年2月19日,國家衞生健康委和國家中醫藥管理局聯合發佈《新型冠狀病毒肺炎診療方案(試行第六版)》。公司產品血必淨注射液分別列入西醫治療重型、危重型病例的治療其他治療措施及中醫治療臨牀治療期(確診病例)重型(氣營兩燔證)、危重型(內閉外脱證)推薦用藥。

血必淨注射液為公司主力產品之一,是公司具有自主知識產權,獨家生產的中藥二類新藥,國家醫保目錄(乙類)品種,是被批准以全身炎症反應綜合徵(SIRS)、膿毒症(Sepsis)、多器官功能障礙綜合徵(MODS)為適應症的藥物。血必淨注射液是目前國內唯一經SFDA批准的治療膿毒症和多臟器功能失常綜合徵的國家二類新藥,具有專利保護。2019年6月3日,血必淨注射液治療重症肺炎的研究論文在國際危重症醫學領域頂級期刊《重症醫學》(CCM)雜誌發表,標誌着該研究成果通過了國際同行專家嚴格審核並獲得一致認可。2019年前三季度,血必淨注射液實現營業收入6.43億元,佔公司營業收入的17.84%。

血必淨注射液作為治療重症肺炎及膿毒症的代表性藥物,因臨牀療效突出,循證證據基礎紮實,得到廣大中西醫臨牀專家的認可及推薦。並作為中醫和西醫治療方案共同推薦的中成藥,連續被納入《新型冠狀病毒肺炎診療方案(試行第四版)、(試行第五版)、(試行第六版)》。最新研究結果顯示:血必淨注射液具有顯著抑制新型冠狀病毒感染誘導的炎症因子過度表達的作用。

公司預計此次《新型冠狀病毒肺炎診療方案(試行第六版)》的發佈將對產品血必淨注射液的市場推廣和銷售產生積極影響,但對公司經營業績的影響暫無法估計。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account